Bioresearch

Cell Movement Explained by Molecular Recycling

Manchester, UK (Scicasts) – Scientists at The University of Manchester have identified the method by which cells control the recycling of molecules, a process that is essential for them to move. The discovery provides researchers with a better understanding of how our bodies heal wounds.

 7 Shares  2,298 Views
A C. elegans worm with green fluorescent protein (GFP) highlighting the APL-1 Alzheimer-related protein in its body. Image: Collin Ewald

Gene May Link Diabetes and Alzheimer’s

New York, NY (Scicasts) – In recent years it became clear that people with diabetes face an ominous prospect – a far greater risk of developing Alzheimer’s disease.

 28 Shares  2,038 Views
Long-Ignored Enzyme Key to Killing Infectious Bacteria

Long-Ignored Enzyme Key to Killing Infectious Bacteria

Columbus, OH (Scicasts) – New research shows that an enzyme that has long been considered relatively useless to the immune response instead has an important role in setting up immune cells to kill infection-causing bacteria.

 10 Shares  1,478 Views
The European HIV/AIDS Market – an Outlook

The European HIV/AIDS Market – an Outlook

Europe is the second largest market for HIV/AIDS therapeutics after the US market. However, it is also a very challenging market for pharmaceutical manufacturers because of the differences in policies across the region. The European HIV/AIDS market poses unique challenges to the manufacturers as well as the public health authorities.

 0 Shares  13,660 Views
Future of Stem Cell Therapeutics- The Global Scenario.

Future of Stem Cell Therapeutics- The Global Scenario.

Their ability to develop into any of the specialized cells found in the body makes stem cells one of the most important research targets for drug discovery. As medical researchers tackle complex conditions, stem cells offer the hope of addressing previously untreatable diseases and providing more effective therapy for ailments currently treated in a less than optimal manner.
 1 Shares  14,585 Views
Changing Dynamics in the European Non-Hodgkin’s Lymphoma Market

Changing Dynamics in the European Non-Hodgkin’s Lymphoma Market

There are about 1.8 million people worldwide living with non-Hodgkin’s lymphoma (NHL). It is the sixth most common form of cancer in Europe. The disease is complicated in nature with about 25-30 sub types. Its incidence in Europe varies from 4 to 14 for every 100,000 people. In the European Union alone approximately 50,000 new cases are diagnosed each year. The risk of developing the disease increases with age, especially among the 55-85 year group. The incidence rate peaks between the ages of 75 and 85 years. With rising life expectancy levels across Europe, the demand for NHL drugs is set to grow.
 0 Shares  23,153 Views
EDC in Clinical trials – Imperative or Not?

EDC in Clinical trials – Imperative or Not?

Clinical trials stage account for more than 50 per cent of the total cost for developing a new drug. The high profile drug withdrawal of Vioxx has brought around a greater regulatory scrutiny on the way clinical trials are conducted. It has been estimated that an average number of patients per clinical trial has increased from 1,700 during the 1980s to around 4,000 people in the current decade. Not only is the number of patients increasing but also is the number of studies required.
 0 Shares  18,430 Views
Niche Participants Carve Opportunities within the Contract Research Organisation Industry

Niche Participants Carve Opportunities within the Contract Research Organisation Industry

Within the past 25 years, research in the pharmaceutical industry has tripled, with the pipelines of the top companies doubling. Stricter regulations, guidelines, price and reimbursement legislation has all resulted in a changing business environment. While pharmaceutical and biotech R&D spending is surpassing $36 billion today and blockbuster drug development levelling off, Contract Research Organisations (CROs) are moving in the direction of becoming either niche specific or large service providers.
 0 Shares  3,960 Views
The European IVD Market: At Present

The European IVD Market: At Present

The total European IVD market is valued at $6.97 billion US and the market is expected to have a slow growth, which is attributed to the increase in the adoption of new technologies in the market. There has been an increased awareness about emerging technologies, especially, in areas such as molecular testing amongst patients and laboratories.
 0 Shares  8,640 Views